Abstract 198P
Background
Geographic access to medical care varies for nearly every specialty in India. Brachytherapy (BT) is emblematic of several of these access difficulties since it necessitates specialized equipment, the capacity to maintain a radioactive source, and particular skill sets. To quantify the unmet infrastructure needs, we conducted this study to report the availability of brachytherapy treatment units in relation to state-level population, and gynaecologic cancer incidence in India.
Methods
The availability of BT resources at the state level in India was obtained from the IAEA database. The population of each state was estimated using data from the Government of India's census. Using National Cancer Registry program data, the number of cancer cases was approximated for each state and union territory. The total number of gynaecological cancers that required BT was determined. BT capacity was estimated at three procedures per unit per day for 240 days(Excluding holidays and weekends) as follows: number of BT units x 240 x 3. The disparity between available and needed infrastructure was used to compute the deficit in BT units. Number of BT facilities available in medical colleges across India were calculated. The BT infrastructure was also compared to those of other nations in terms of the number of BT units available per million people and for various malignancies.
Results
India has 1 brachytherapy unit every 42,93,031 population. With respect to state wise data, 21 states and union territories had deficits of brachytherapy units. The maximum deficit was seen in Uttar Pradesh. The maximum units per 10,000 cancer patients was noted in Delhi (7) and the least was noted in the North Eastern states (<1). In brachytherapy of gynaecological cancers a deficit ranging from 1-75 units were noted across the states. It was noted that only 104 out of the 613 medical colleges in India had BT facilities. India had 1 BT machine for every 4181 cancer patients when compared to USA ( 2956 patients), Germany (2754 patients) and Japan (4303 patients).
Conclusions
The study identified the deficits of BT facilities in India and provides a direction for the development of BT infrastructure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abhishek Krishna.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03